Pfizer has beaten earnings estimates in all 4 recent quarters with an average 23.4% upside surprise and converts income to free cash flow at 165%, but near-term growth is weak, the stock trades at analyst targets with only 1% upside, and the put/call ratio of 11.4 signals extreme hedging activity.
Thesis pillars
- Perfect Beat Streak High Surprise→Stable
- Fcf Conversion Quality↓Deteriorating
- Product Concentration Weak Growth↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pfizer, Inc. (PFE) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $26.67, but acceptable to hold if already in. Reasons: Concentration risk — Product: top-12 products (65.0%); Analyst target reached - limited upside remaining.
Pfizer discovers, develops, manufactures, and sells biopharmaceutical products worldwide through a single Biopharma reportable segment, marketing medicines and vaccines to wholesalers, governments, hospitals, and retailers in approximately 200 countries. The company's 12 largest... Read more
Hold if already holding. Not a fresh buy at $26.67, but acceptable to hold if already in. Reasons: Concentration risk — Product: top-12 products (65.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 87d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-08-09Recent Developments — Pfizer, Inc.
Latest news
- NEWS Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - qz.com — qz.com neutral
- NEWS Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy? - Yahoo Finance — Yahoo Finance neutral
- NEWS Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy? - finance.yahoo.com — finance.yahoo.com neutral
- NEWS Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy? - Zacks Investment Research — Zacks Investment Research neutral
- NEWS How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise - Investor's Business Daily — Investor's Business Daily positive
Generated 2026-08-09T07:42:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProducttop-12 products65%10-K Item 1A: 'revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025'
- LOWProductEliquis13%10-K Item 1A: 'Eliquis accounted for 13% of Total revenues in 2025'
- MEDIUMGeographicinternational operations41%10-K Item 1: 'Revenues from operations outside the U.S. of $25.5 billion, $24.9 billion and $31.4 billion accounted for 41%, 39% and 53% of Total revenues in 2025, 2024 and 2023, respectively'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $26.67, but acceptable to hold if already in. Reasons: Concentration risk — Product: top-12 products (65.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $30.77 (+15.4%), stop $25.74 (−3.6%), A.R:R -0.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $30.77 (-3.7% upside). Target $30.77 (+15.4%), stop $25.74 (−3.6%), A.R:R -0.3:1. Stop-loss: $25.74.
Concentration risk — Product: top-12 products (65.0%); Analyst target reached - limited upside remaining; Weak growth.
Pfizer, Inc. trades at a P/E of 34.3 (forward 9.3). TrendMatrix value score: 6.0/10. Verdict: Hold.
36 analysts cover PFE with a consensus score of 3.5/5. Average price target: $29.
What does Pfizer, Inc. do?Pfizer discovers, develops, manufactures, and sells biopharmaceutical products worldwide through a single Biopharma...
Pfizer discovers, develops, manufactures, and sells biopharmaceutical products worldwide through a single Biopharma reportable segment, marketing medicines and vaccines to wholesalers, governments, hospitals, and retailers in approximately 200 countries. The company's 12 largest products each exceeded $1 billion in revenue and together accounted for 65% of total revenues in 2025; international operations contributed 41% of total revenues.